In summary, our study has unraveled the intricate mechanisms through which KRAS mutations orchestrate the ERK/JNK signaling pathways, posttranslational modifications of ALKBH5, and mRNA m6A modification to confer platinum resistance in NSCLC cells. Here, MAPK8 is linked to non-small cell lung carcinoma.